Notice: Policy on Bioequivalence Standards for Highly Variable Drug Products

You're currently viewing an old version of this dataset. Some resources may no longer exist or the dataset may not display correctly. To see the current version, click here.

This Notice serves to inform sponsors of drug submissions pursuant to Division C.08 of the Food and Drug Regulations (that is [i.e.], new drug and abbreviated new drug submissions) of changes in Health Canada's comparative bioavailability requirements for drug products which exhibit large pharmacokinetic within-subject variation in extent of absorption, as measured by area under the concentration versus time curve (AUC).

Data and Resources

Similar records